Investor Rights Law Firm Investigates Corporate Transactions
Investor rights law firm Halper Sadeh LLC has launched investigations into four companies for potential violations of federal securities laws and/or breaches of fiduciary duties to shareholders.
NEW YORK, July 9, 2026 – Investor rights law firm Halper Sadeh LLC is investigating Theravance Biopharma, Inc. (NASDAQ: TBPH) concerning its sale to Zymeworks Inc. for $17.00 per share. The firm is also investigating Iridium Communications Inc. (NASDAQ: IRDM) regarding its sale to Rocket Lab Corporation, LCI Industries (NYSE: LCII) for its sale to Patrick Industries, Inc., and Patrick Industries, Inc. (NASDAQ: PATK) concerning its merger with LCI Industries.
The investigations focus on potential violations of federal securities laws and/or breaches of fiduciary duties owed to shareholders. Halper Sadeh LLC is examining whether insiders may receive substantial financial benefits not available to ordinary shareholders, or if the terms of the proposed transactions could limit superior competing offers.
Theravance Biopharma is being sold to Zymeworks for a price of $17.00 per share. Iridium Communications is being sold to Rocket Lab Corporation for a combination of cash and Rocket Lab common stock. LCI Industries is being sold to Patrick Industries through an all-stock transaction, following which Patrick Industries shareholders are expected to own approximately 52% of the combined company.
Halper Sadeh LLC encourages shareholders of these companies to contact the firm to discuss their rights and options. The firm stated that the investigations may seek increased consideration, additional disclosures, or other benefits for shareholders. The firm operates on a contingency fee basis, meaning clients would not be responsible for out-of-pocket legal fees or expenses.